Anticoagulant Reversal Drugs Market Size, Share, Trends, Growth 2030

Anticoagulant Reversal Drugs Market Size:

The global anticoagulant reversal drugs market size was worth around US$ 0.83 Billion in 2021 and is projected to grow around USD 2.25 Billion by 2030, with a compounded annual growth rate (CAGR) of roughly 11.27% from 2022 to 2030. The report analyzes the global anticoagulant reversal drugs market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the anticoagulant reversal drugs market.

Request Free Sample

Get more information about this report - Request Free Sample PDF

Anticoagulant Reversal Drugs Market: Overview

Anticoagulants are medications that are essentially used to ward off the layer of blood from getting thick. Anticoagulants play a major role in helping patients suffering from lethal conditions including pulmonary embolisms and heart attacks. Several reversal agents such as Xarelto and Eliquis are extensively used to counter the effect of severe situations of uncontrolled and prolonged bleeding. Vitamin K or Praxbind (idarucizumab) is another such medication that is given to prevent anticoagulants from working, and hence it has been approved for emergency situations.

Key Insights

• As per the analysis shared by our research analyst, the global anticoagulant reversal drugs market is expected to grow annually at a promising CAGR of around 11.27% during the forecast period 2022-2030.
• In terms of revenue, the global anticoagulant reversal drugs market size was valued at around US$ 0.83 Billion in 2021 and is projected to grow to around USD 2.25 Billion by 2030.
• Anticoagulant reversal drugs are special medications that are usually prescribed in particular instances, such as anticoagulant overdose, unanticipated surgery, and uncontrolled bleeding where anticoagulant reversal drugs are essentially taken to reverse the anticoagulant effect. These drugs also protect patients who suffer from blood clots which is the case in certain life-threatening diseases including strokes and heart attacks.
• Based on product type, the coagulation factors segment held the largest market share in 2021 and is further predicted to grow at a promising CAGR during the forecast period.
• Based on distribution channel, the hospital pharmacy segment held the dominating market share in 2021 and is further predicted to grow at the highest CAGR during the forecast period.
• Based on region, the North American region held the dominating market share in 2021 and is further predicted to grow at a significant CAGR during the forecast period.

Request Free Sample

To know more about this report, Rquest a sample copy

Anticoagulant Reversal Drugs Market: Drivers

Significant surge in cases of bleeding disorders and abnormal blood coagulation among people drives the market growth

There has been an increase in the prevalence of bleeding disorders among people. Gastrointestinal (GI) hemorrhage is one of the most common disorders that account for about 50% of main bleeding events. Intracranial hemorrhage (ICH) is another major disorder that is increasingly prevalent among patients who are treated with DOAC (Direct-acting Oral Anticoagulants).

Besides, growing cases of heart attacks, the adoption of a sedentary lifestyle, and a surge in the geriatric population further drive the growth of the market. In addition, an increase in the prevalence of atrial fibrillation (AFib), Von Willebrand Disease (VWD), anemia, and other bleeding diseases that cause abnormal blood coagulation subsequently boost the demand for anticoagulant reversal drugs.

Anticoagulant Reversal Drugs Market: Restraints

Extortionate cost of anticoagulant reversal drugs hinders the growth of the market

High cost of therapy and anticoagulant reversal drugs might restrict the growth of the market to an extent as it might not be feasible for patients who are in dire need of these medications but do not tend to afford them. This might result in reduced demand for these drugs, especially during the economic crisis in various countries.

Anticoagulant Reversal Drugs Market: Opportunities

Increase in adoption of new technologies and development of novel medication offer remunerative opportunities for market growth

Persistent technological advancements and improvements in healthcare infrastructure in various countries across the globe lead the way. This is mainly due to remarkable R&D activities undertaken by eminent companies so as to effectively revamp and improve the laboratory clinics for various drug discovery and drug testing procedures. The U.S. Centers for Medicare and Medicaid Services (CMS) have granted the new technology add-on payment (NTAP) status to particular medications that are specially designed to act on a few of the anticoagulants. This status appreciably improves the patient’s access to drugs with supplementary Medicare reimbursement in hospitals and clinics.

Anticoagulant Reversal Drugs Market: Challenges

Certain side effects linked with the application of drugs may act as a challenge to the growth of the market

Application of some of the medications can cause serious complications of excessive bleeding that can have a detrimental impact on the health of the individual, particularly among the geriatric population. Thus, the adverse side effects of the drugs can limit act as a challenge to the growth of the anticoagulant reversal drugs industry.

Anticoagulant Reversal Drugs Market: Segmentation

The global anticoagulant reversal drugs market is segmented based on product type, distribution channel, and region.

Based on product type, the global market is bifurcated into idarucizumab, protamine, prothrombin complex concentrates, coagulation factors, phytonadione, andexanet alfa, and others. The coagulation factors segment held the largest market share in 2021 and is further expected to surge exponentially at a promising CAGR during the forecast period.

The major reason behind the growth of this segment is that, in case of any injury, they help to form a blood clot in patients so as to effectively stop bleeding. Besides, during the pandemic, it was witnessed that COVID-19 had caused blood clotting in a lot of patients. Hence, coagulopathy of differing extremities was witnessed in most of the COVID-19-infected patients.

Therefore, comprehensive research on numerous factors impacting coagulation and bleeding among COVID-19 patients was essentially undertaken to comprehend the pathophysiology of the patients. These factors drive the growth of the coagulation factors segment in the anticoagulant reversal drugs industry during the forecast period.

Based on distribution channel, the global market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2021 and is further predicted to grow rapidly at a significant CAGR during the forecast period.

This is mainly because hospitals are the major hubs and centers for the treatment and diagnosis of various bleeding disorders experienced by patients. Thus, there has been an increase in the usage of anticoagulant reversal drugs in surgical procedures to conclusively limit immoderate bleeding and lethal hemorrhage disorders in patients. In addition, hospital pharmacies increasingly tend to restock these drugs, making them frequently available as they are helpful in emergency situations. These factors are projected to drive the growth of the segment during the forecast period.

Recent Developments:

• In March 2022, Ondexxya became the first approved reversal agent in Japan for patients who are undergoing the treatment of Factor Xa inhibitors rivaroxaban, apixaban, or edoxaban, where reversal of anticoagulation is of paramount importance because of lethal or immoderate bleeding. The approval of the drug was done by the Japanese Ministry of Health, Labour and Welfare by following the remarkable conclusions on favorable results from the ANNEXA-4 Phase III clinical trial that portrayed Ondexxya considerably reversing anti-FXa activity in patients who suffered from lethal bleeding. Japan also became the first country to facilitate complete regulatory approval of Ondexxya for use. This provides a key advancement in the diagnosis of patients who are hospitalized and suffering from pernicious bleeding.
• In July 2022, a team led by UNC Charlotte researcher named Kirill Afonin announced the launch of a new anticoagulant platform that can be beneficially used during dialysis, heart surgeries, and other procedures for better treatment of patients.

Anticoagulant Reversal Drugs Market Report Scope:

Anticoagulant Reversal Drugs Market: Regional Analysis

North America to hold the dominant position in the global market

The North American region held the largest market share in 2021 and is further projected to grow exponentially at a promising CAGR during the forecast period. The main reason behind the growth of the anticoagulant reversal drugs market in this region is the growing cases of surgeries, the rise in geriatric population, and the favorable approval of drugs for lethal bleeding disorders in the region.

In addition, the availability of better healthcare infrastructure, an increase in R&D activities among eminent players in the market. Furthermore, the high healthcare expenditure and encouraging healthcare reimbursement policies for unaffordable or costly drugs among patients will bolster the growth of the anticoagulant reversal drugs industry during the forecast period.

Anticoagulant Reversal Drugs Market: Competitive Analysis

The global anticoagulant reversal drugs market is dominated by players such as:

• Pfizer Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Mylan N.V.
• Novartis AG
• Lupin
• Cipla Inc
• Aurobindo Pharma
• Sanofi
• Merck & Co. Inc
• Amneal Pharmaceuticals LLC.
• Alvogen
• Bausch Health Companies Inc.

The global anticoagulant reversal drugs market is segmented as follows:

By Product Type

• Idarucizumab
• Protamine
• Prothrombin Complex Concentrates
• Coagulation Factors
• Phytonadione
• Andexanet Alfa
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa